pancreatic cancer
Conditions
Interventions
None listed
Sponsors
Kanazawa University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria below when they are registered. Gender, admission or outpatient clinic will not be assessed. 1. pancreas cancer patient, chronic pancreatitis patient, intraductal papillary mucinous neoplasm, healthy individual. <in case of pancreatic cancer patients> patients who are diagnosed to be pancreatic cancer by image or pathology. <in case of chronic pancreatitis, intraductal papillary mucinous neoplasm> patients who are diagnosed with chronic pancreatitis or intraductal papillary mucinous neoplasm by image or pathology. <in case of healthy individual> the individual who comes to undergo medical check-up and is considered to be healthy judged from the history by the previous year and diagnostic questionnaire on the day of medical check-up. 2. Patients aged more than equal 40 years and less than 90 years old. 3. Patients who give the informed consent.
Exclusion criteria
Exclusion criteria: The patients who meet any of the criteria below will be excluded when they are registered. 1. Patients who have been diagnosed with malignancy(excluding pancreatic cancer) within 5 years of the date of the informed consent. 2. Patients who have been or is currently treated with immunosuppressant, oral steroid within one year of the date of the informed consent. 3. Patients who have been treated with anti-cancer drug within 6 months of the date of the informed consent. 4. Patients who are infected with hepatitis B, hepatitis C or other infectious diseases. 5. Patients who are judged to be not appropriate for entry by the trial responsible (collaborative) doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| sensitivity, specificity | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. positive predictive value and negative predictive value of blood mRNA test 2. sensitivity, specificity, positive predictive value and negative predictive value of CEA 3. sensitivity, specificity, positive predictive value and negative predictive value of CA19-9 | — |
Countries
Japan
Contacts
Public ContactYoshio Sakai
Kanazawa University school of medicine
Outcome results
None listed